Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal
Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...
GlobalData on MSN5d
AbbVie and Xilio to collaborate on antibody-based immunotherapiesAbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...
AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...
Xilio Therapeutics announces collaboration with AbbVie for tumor-activated immunotherapies, receiving $52 million upfront, extending cash runway to 2026. Xilio Therapeutics, Inc., a clinical-stage ...
NORTH CHICAGO, Ill. - Pharmaceutical (TADAWUL:2070) giant AbbVie (NYSE:ABBV), a $339 billion market cap company with a strong financial health rating according to InvestingPro, and biotech firm Xilio ...
AbbVie and Xilio Therapeutics have announced a collaboration to develop innovative tumor-activated immunotherapies, including masked T-cell engagers, utilizing Xilio’s proprietary technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback